Sionna Therapeutics Inc(SION) - 2025 Q2 - Quarterly Results

Waltham, Mass.,August 11, 2025 (GLOBE NEWSWIRE) – Sionna Therapeutics, Inc.(Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today reported financial results for the quarter ended June 30, 2025, and provided a business update. "We are pleased with the progress we've made this past qu ...